NCT06211712View on ClinicalTrials.gov

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Experimental: Human Urinary Kallidinogenase

Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.

DRUG

Placebo Comparator: Placebo

Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.

Trial Locations (1)

200040

RECRUITING

Huashan Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Stroke Association

UNKNOWN

lead

Huashan Hospital

OTHER

NCT06211712 - Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion | Biotech Hunter | Biotech Hunter